1. Team 8
CHEN 5970, Spring 2016
Engineered Corneal Stroma for use in Corneal Transplants
Kelsey Henderson
Matthew Lopez
Quinn Otte

2. Executive Summary
The objective of the proposed project is to create a potential direction for a tissue engineered
corneal stroma for either direct transplantation or combination with other tissue engineered
corneal layers prior to transplantation. The need for corneal transplants is increasing, just as the
number of viable tissue donors is decreasing. The rise of LASIK is widely decreasing the number
of useable corneal tissues in the US, due to the LASIK process thinning the cornea and making it
unusable for transplants.1
For many pathologies, replacing only the stroma is an effective
treatment.2
For a total cornea transplant, the proposed product can be combined with engineered
versions of the remaining corneal layers for a final product. The final design uses a silk fibroin
scaffold seeded with keratocytes differentiated from dental pulp stem cells.

3. Background
The eye is an incredibly complex organ, acting as a biological transducer to turn light into
electrical signals to the brain via the optic nerve. The cornea is the most anterior part of the eye,
and is the first part of the eye that comes into contact with visible light. Part of its function is as
the first lens, directing light toward the interior lens that exists behind the iris. It is also
protective, selectively allowing small molecules like oxygen to diffuse through but keeping out
larger proteins and debris.3
These two main functions are critical to the overall function of the
eye. The loss of one or both of these functions of the cornea will lead to a damaged eye, which
nearly always leads to a decreased quality of life by inducing chronic pain, loss of eyesight,
and/or aesthetic degeneration.
The cornea is comprised of three main layers: the epithelium, stroma, and endothelium. The
epithelium is the outer layer; it is highly innervated and comprised mostly of tightly packed
stratified squamous cells. These cells are highly proliferative and are attached to the stroma by
the Bowman’s membrane: an acellular collagen membrane. The endothelium is a single layer of
flattened, highly specialized cells. These cells are held together by tight junctions and control
mass transport between the cornea and the interior of the eye. As such, it is responsible for
maintaining the slightly dehydrated state of the stroma necessary to maintain optical clarity. The
endothelium remains attached to the stroma via the Descemet membrane: also an acellular
collagen layer. These acellular layers permit the epithelium and endothelium to be surgically
removed from the stroma, allowing for the independent transplantation of engineered stromal
tissue.3
The stroma makes up 90% of the cornea’s thickness; it is about 465μm on average. As the
thickest part of the cornea, it is responsible for the optical properties of the tissue. It is comprised
mostly of ECM components, the vast majority being collagen. The organization of this collagen
is the key to maintaining optical clarity. Collagen is an individual fibril, which bundle together in
parallel “ropes” called lamellae. The fibrils must be parallel within the lamellae, which are in
turn arranged orthogonally to one another, with about 55µm spacing between fibrils.4
If this
organization breaks down (as it often does with some of the diseases listed), then optical clarity
is compromised and eyesight suffers. The collagen is produced by keratocytes, which only
occupy 5-10% of the stroma’s total volume. This is an advantageous property for tissue
engineers, as target cell density to maintain a functional tissue is relatively low compared to
other tissues. Keratocytes have a low rate of proliferation; they are highly specialized
descendants of mesenchymal stem cells of the neural crest.5
The cornea is vulnerable to several infirmities that can be remedied by a corneal transplant,
either total or exclusively stromal. Mechanical injury to the eye sometimes can be require a
transplant, as well as corneal ulcers which are usually a side effect of severe infections. Ulcers
from infections are highly likely to form if the infection is left untreated, due to the relative
absence of immune system cells in the cornea. However, this locally suppressed immune system
is helpful during a transplant, as an inflammatory response and foreign body rejection is easier to
avoid. Keratoconis is describes any pathology that causes a cornea to become misshapen over
time. Some conditions are genetic, such as Fuch’s dystrophy or macular corneal degradation.

4. Fuch’s dystrophy causes a failure of the endothelium, leading to over-hydration of the stroma
and a loss of optical clarity and shape. Macular corneal degeneration affects patients early in
life—usually before ten years of age. It is a painful malfunction of keratocytes, and is only
treated by a transplant.6
This project aims to create a viable replacement for donor tissue—the
only treatment for most of these ocular diseases.

5. Review of existing clinical therapies
Currently, there exists two main types of corneal transplants, known as keratoplasty, which differ
in the way and the amount of the cornea that is transplanted. The first type, penetrating
keratoplasty (PK), is the oldest surgical method used for corneal transplants. All three main
layers of the cornea (epithelium, stroma, and endothelium) are surgically removed and replaced
with a donor cornea. After the donor cornea is positioned correctly, it is then immobilized with
sutures so that healing can ensue. When this method is used, the average recovery time for
complete restoration of the patient’s vision (assuming no complications) is about 15 months.
The second surgical method, known as anterior lamellar keratoplasty (ALK), is the preferred
method for corneal transplants. The success of this method is due to limiting the layers of the
cornea that are surgically removed. This method involves dissecting the cornea into two layers
then removing and subsequently replacing the outer layer. A refinement of ALK, known as deep
anterior lamellar keratoplasty (DALK), removes the stroma, leaving behind both the endothelium
and epithelium. Both ALK and DALK reduce the necessary amount of healing time to mere
weeks rather than months.
As always when using donor tissue, there exists the possibility for disease transmission.
Although this has been reported as a rare event, the potential is nevertheless present.7
Complications associated with corneal transplants include cornea graft rejection and infection of
the eye. The more serious of these two complications is graft rejection, occurring in 5 to 30
percent of patients.8
However, the use of ALK and DALK avoid the possibility of this
complication due to the ability of the epithelium and stromal cells to regenerate. Another
problem is that donated corneas usually only last about 10 years.9
Perhaps the most severe
limitation to the use of corneal transplant methods is the availability of donated corneas. In future
years, the supply of donated corneas will decrease due to the increasing use of LASIK surgery.
LASIK surgery corrects a person’s vision but eliminates the cornea’s ability to be donated
posthumously.10
Therefore, any person who has undergone LASIK surgery is not considered a
possible donor.

6. Review of existing corneal tissue engineering strategies
Due to the decreasing supply of donated corneas for the use in corneal transplants, research and
development of engineered corneal tissue as a replacement to donor corneas has become an area
of high interest.
There are many different approaches being used to develop a viable scaffold for use as a corneal
allograft tissue. These approaches vary from the use of regenerative medicine techniques to the
development of synthetic polymers.
Natural polymer techniques provide vast potential for use as a scaffold material due to the
inherent biocompatibility, biofunctionality, and vast availability. Therefore, their use as a
scaffold material averts the need to focus attention on these considerations, allowing the
appropriation of this attention to other, more specific concerns. Synthetic polymer techniques, on
the other hand, offer benefits in other areas such as the potential for customized properties, the
lack of batch to batch variability, and the lack of potential for disease transmission. Many of the
current studies combine both natural and synthetic polymers. Uchino et al designed a scaffold
material composed of an amniotic membrane (AM) immobilized polyvinyl alcohol (PVA) in
order to combine the stability of synthetic polymers with the biocompatibility of natural
polymers.11
Control over the stability of the AM (natural component) proved to be the most
difficult obstacle to overcome. Another combination of natural and synthetic polymers, collagen-
immobilized polyvinyl alcohol (PVA-COL), was used as a scaffold material.12
Mayashita et al
determined that through the use of PVA-COL, that a stratified human epithelium was found in 6
of the 9 trials and that the stratified epithelium had the same histological and functional
characteristics of a healthy epithelium. However, the studies performed by Uchino et al
determined that the use of PVA-COL to support the growth of rabbit epithelium tissue resulted in
defects in approximately half of the trials.13
Collagen vitrigel (CV) was also tested for the
potential viability as a scaffold material.14
This study showed that keratocytes cultured onto CV
exhibited the correct morphology with both endothelial and epithelial cells exhibiting adhesive
structures as well. This technique shows that perhaps the most promise for a viable material for
use as a corneal scaffold is one derived from silkworm fibroin.
Using silk as a biomaterial has been extensively studied.15
Madden et al demonstrated that an
endothelial layer can be grown on silk fibroin membranes.16
Liu et al demonstrated that silk
fibroin supports corneal epithelial cells to proliferate, differentiate, and retain the normal
epithelium phenotype.17
It was also shown that silk fibroin exhibited transparency comparable to
the native corneal tissue, making it the most ideal candidate tested thus far for application in
keratoplasty. This material has been shown to exhibit biocompatibility, sufficient transport
properties (including the ability for oxygen to diffuse into the material), optical clarity, and the
ability to degrade without creating an immune response. Silk fibroin has also been shown to
support the growth of the various cell types that are found in the human cornea. Therefore, silk
fibroin is proposed as the scaffolding material that will be used in the development of the
proposed material.

7. Extensive study of different methods of culturing keratocytes through the use of various types of
stem cells has been done. It has also demonstrated how effectively human limbal epithelial
(HLE) cells can be cultivated through the use corneal stromal stem cells (CSSC).18
In this study,
it was shown that a mixed population of HLE cells and CSSCs were successfully cultivated
while maintaining stem cell phenotype for both types of cells. Other research has been successful
in differentiating neural crest-derived adult dental pulp cells into keratocytes in vitro and in vivo
as well as generating a tissue-engineered corneal stromal-like tissue.19
This provides a great
option for the type of cells as well as the source of the cells that could lead to a viable tissue-
engineered corneal allograft.

8. Engineering Considerations
As with designing any tissue engineered product, there are various aspects that must be
considered prior to making the choice for materials and cell sources. The most important
consideration is always biocompatibility. If the proposed product is not viable due to
biocompatibility reasons, it is not likely to succeed no matter the amount of adjustments that are
made. For the proposed product, degradation plays a key role. The engineered material will need
to degrade at the same rate that cells are proliferating. This process mocks how the cornea
naturally operates, as it is continually renewing itself. A major factor that plays a role in
determining if the engineered product will be commercially viable is the cell source. Since an
engineered tissue will be composed of billions of cells on average, if the cell source that is used
is not capable of supplying the necessary amount of cells, production simply cannot ever take
place. The process of deciding on a choice of material involves considerations that a more
specific to the tissue that is being proposed. Due to an absence of a vascular network, the oxygen
necessary for cellular function will need to diffuse into the material from the surrounding air.
Therefore, our material choice will need to be sufficiently permeable with respect to oxygen.
Since our proposed material will be used to treat problems associated with a person’s vision,
optical clarity is paramount when choosing a material. It was found that the optical clarity of the
material was mostly dependent on these properties: parallel fibrils within lamella, orthogonally
aligned lamellae, constant diameter of lamellae.

9. Our Proposed Design
A primary measure of success of any engineered tissue is the ability of the material to support
cell attachment and proliferation. When human corneal fibroblasts were cultured on multiple,
stacked silk sheets, random cell and ECM orientation was observed. Because of the necessary
level of organization required of the stroma, a new strategy must be used. Studies have shown
that coupling silk biomaterials with RGD enhances cell attachment, proliferation, and alignment
as well as ECM production. The complex structure of the stroma can be replicated by covalently
linking arginine-glycine- aspartic acid (RGD) in the correct lamellar structure, and the cells can
then be cultured onto the biomaterial. Studies have shown that this will cause the cells to
properly align on the surface of the silk. The RGD coupling also increases cell proliferation and
production of ECM components, specifically collagen I and II and proteoglycans. 15
Another important consideration is degradation properties of our design; the degradation rates
need to match the regeneration rate of the corneal stroma. Silk is made up of pseudo-crystalline
lattice structures called β-sheets, which determine its degradation rate. Increased β-sheet content
increases the density of the silk material and provides fewer spaces for protease XIV and α-
chymotrypsin to contact the silk and induce hydrolysis. β-sheet content also is responsible for the
mechanical stiffness of the biomaterial. Thus, an optimum β-sheet content is required: too much
will prevent the silk from degrading fast enough and too little will not provide enough support
for the engineered tissue. Multiple processes are used to generate the physical crosslinks
necessary to induce β-sheet production, but the most easily tunable is water vapor annealing and
slow drying.20
Annealing is the process by which a substance is heated past its recrystallization
temperature and then cooled, resulting in the removal of internal stresses.21
Shang et al have
developed a novel method of water vapor annealing followed by enzymatic pretreatment that
allows the tunability of the β-sheet content and therefore degradability. The β-sheet content was
optimized at 17-18% which can be achieved by water vapor annealing for 30-45 minutes. This β-
sheet content will support the structure of the engineered tissue while still allowing for
degradation at the desired rate. Additionally, this low β-sheet content increased the transmittance
of light in the visible range through the silk biomaterial.20
Most of the research previously done exploring silk fibroin has used human corneal stromal stem
cells or human corneal fibroblasts to examine the viability and proliferation within the scaffold.
However, because of the lack availability of healthy corneal cells and the desire for
personalization of this therapy, we decided to seek other stem cell options. Dental pulp is a
vascularized connective tissue at the center of the tooth and contains multipotent mesenchymal
stem cells. These stem cells are neural-crest derived and thus share developmental origins with
keratocytes. They can be harvested through minimally invasive endodontic procedures and then
differentiated into keratocytes. After differentiation, dental pulp stem cells yield the
characteristic gene and protein expression. Additionally, keratocan and keratin sulfate were
expressed which are responsible for the uniform spacing of collagen fibrils in the native
microenvironment. Ideally, this would allow the use of an autologous cell source; dental pulp
stem cells could be harvest from banked exfoliated deciduous teeth or routine extraction of third
molars. If neither of these options were available, cells could be harvested from the patient’s own

10. second molars or from allogenic dental sources. Typical protocol calls for the cells to be
differentiated in vitro, then seeded onto the scaffold of choice.22
Although dental pulp cell
derived keratocytes have not been combined with silk fibroin biomaterials, we feel that the
success of this material and these cells will be additive when combined.
Previously tissue engineered stroma from silk fibroin sheets have been synthesized in 2-4 μm
thicknesses. Sheets have been stacked by using applied pressure on the edges of the scaffold, but
200 of these sheets would be needed to generate a full thickness cornea; so far research has only
extended to layer a few sheets at a time.15
We would propose attempting to make several stacks
of silk sheets and then layer those stacks on one another or attempt to increase the thickness of
one sheet, but little research on these methods was found.

11. Design Tests
Many tests would have to be performed on our proposed strategy to determine its efficacy and
viability for treatment. Initially, we would want to perform as many acellular, in vitro tests as
possible. The silk sheets would be synthesized, including RGD coupling and the short time water
vapor annealing. Degradation tests would be performed: the mass of the material would be
determined over a period of time and the degradation products would be tested for toxicity.
Additionally, the mechanical stiffness would be quantified to ensure adequate support of the
tissue. Gas diffusion tests would also be necessary to determine if the required amount of oxygen
can diffuse through the material in the desired amount of time. Layering the stacks of silk sheets
could also be tested acellularly, at first. Eventually, we would probably want to culture cells on
each of the sheets before stacking them because the cells could not easily migrate the entire
400μm depth. Of course, all of these tests would need to be repeated once cells were introduced
into the scaffold to verify the results.
After harvesting the dental pulp stem cells and differentiating them, we would need to test gene
and protein expression to ensure successful differentiation. Our keratocytes would then be
seeded onto the silk scaffolds and live/dead assays would be performed to ensure the viability of
the cells since dental pulp-derived keratocytes have not been combined with silk fibroin before.
We would also want to ensure that key ECM components—collagen I, V, and VI, proteoglycans,
keratocans, lumican and keratan sulfate—were being produced in the biomaterial in the same
concentrations as in the native microenvironment. To ensure the clarity of the tissue, we would
perform image analysis to examine the size and spacing of the lamellae and the orientation of the
fibrils and lamellae. Furthermore, the amount of visible light wavelengths that pass through the
biomaterial would be quantified.
Initial biocompatibility tests could be performed in vitro but would ultimately need to be moved
to in vivo models. The activation of keratocytes to corneal fibroblasts and the deposition of scar
tissue are both indicative of rejection. The formation of vascular networks and a hazy appearance
also denote complications with biocompatibility as well as interfere with optical transparency15
.
Eventually, tests would be performed in vivo, beginning with mouse models and hopefully
working up to clinical trials. The end goal would be a replacement for allogenic donor tissue that
would be at least as effective for the patient and easy for the surgeon to transplant by already-
familiar methods.

12. Conclusions
The need for a viable engineered corneal tissue is increasing due to the decreasing number of
usable donor corneas. A majority of the corneal transplants performed each year are performed
by replacing the epithelium and stroma layers of the cornea. A silk fibroin scaffold has been
shown to be biocompatible, have inherent transport properties that are necessary for corneal
function, and been shown to support the proliferation of endothelial cells.23,24
Furthermore, the
use of dental pulp stem cells as a cell source for keratocytes has been shown to be a viable
option.25
Therefore, a novel use of a silk fibroin scaffold seeded with keratocytes differentiated
from dental pulp stem cells has been proposed for the use in cornea transplants.

13. References
1: Liu, Jingbo et al. Silk Fibroin as a Biomaterial Substrate for Corneal Epithelial Cell Sheet
Generation.Investigative Ophthalmology & Visual Science53.7 (2012): 4130–PMC. Web. 22
Apr. 2016.
2: Cornea Transplant: Surgery, Recovery, Success Rate, and More." WebMD. WebMD, n.d.
Web. 08 Mar. 2016.
3: "Facts About The Cornea And Corneal Disease | National Eye Institute". Nei.nih.gov. N.p.,
2016. Web. 24 Apr. 2016.
4: Jester JV (April 2008). "Corneal crystallins and the development of cellular transparency".
Semin. Cell Dev. Biol. 19 (2): 82–93.doi:10.1016/j.semcdb.2007.09.015. PMC 2275913.PMID
17997336
5: West-Mays, Judith A., and Dhruva J. Dwivedi. "The Keratocyte: Corneal Stromal Cell With
Variable Repair Phenotypes". The International Journal of Biochemistry & Cell Biology 38.10
(2006): 1625-1631. Web. 11 Mar. 2016.
6: "Facts About The Cornea And Corneal Disease | National Eye Institute". Nei.nih.gov. N.p.,
2016. Web. 24 Apr. 2016.
7: O'day, Denis M. "Diseases Potentially Transmitted Through Corneal Transplantation."
Ophthalmology 96.8 (1989): 1133-138. Web.
8: "Cornea Transplant: How It Works, With Info on Donating Tissue." All About Vision. N.p.,
n.d. Web. 21 Apr. 2016.
9: "Cornea Transplant ." Cornea Transplant. N.p., n.d. Web. 21 Apr. 2016.
<http://www.nhs.uk/Conditions/corneatransplant/Pages/Introduction.aspx>.
10: "Eye Donor Awareness: Frequently Asked Questions." University of Iowa Hospitals and
Clinics. N.p., n.d. Web. 21 Apr. 2016. <https://www.uihealthcare.org/eye-donor-awareness-
frequently-asked-questions/>.
11: Uchino, Shimmura S. "Amniotic Membrane Immobilized Poly(vinyl Alcohol) Hybrid
Polymer as an Artificial Cornea Scaffold That Supports a Stratified and Differentiated Corneal
Epithelium." National Center for Biotechnology Information. U.S. National Library of Medicine,
n.d. Web. 22 Apr. 2016.
12: Mayashita, H. "Collagen-immobilized Hydrogel as a Material for Lamellar
Keratoplasty." National Center for Biotechnology Information. U.S. National Library of
Medicine, n.d. Web. 22 Apr. 2016.

14. 13: Wang, Hai-Yan, Rui-Hua Wei, and Shao-Zhen Zhao. "Evaluation of Corneal Cell Growth on
Tissue Engineering Materials as Artificial Cornea Scaffolds." International Journal of
Ophthalmology. International Journal of Ophthalmology Press, n.d. Web. 22 Apr. 2016.
14: McIntosh Ambrose, W., Salahuddin, A., So, S., Ng, S., Ponce Márquez, S., Takezawa, T.,
Schein, O. and Elisseeff, J. (2009), Collagen vitrigel membranes for the in vitro reconstruction of
separate corneal epithelial, stromal, and endothelial cell layers. J. Biomed. Mater. Res.,
90B: 818–831. doi: 10.1002/jbm.b.31351
15: GHEZZI, C. E., RNJAK-KOVACINA, J. AND KAPLAN, D. L. “Corneal Tissue
Engineering: Recent Advances and Future Perspectives.” Tissue Engineering Part B: Reviews
2015, 21, 278-287.
16: Madden, Peter W. "Human Corneal Endothelial Cell Growth on a Silk Fibroin
Membrane." ResearchGate. N.p., n.d. Web. 22 Apr. 2016.
17: Liu, Jingbo et al. “Silk Fibroin as a Biomaterial Substrate for Corneal Epithelial Cell Sheet
Generation.” Investigative Ophthalmology & Visual Science 53.7 (2012): 4130–4138. PMC.
Web. 22 Apr. 2016.
18: Kureshi, Alvena K et al. “Human Corneal Stromal Stem Cells Support Limbal Epithelial
Cells Cultured on RAFT Tissue Equivalents.” Scientific Reports 5 (2015): 16186. PMC. Web. 22
Apr. 2016.
19: Syed-Picard, Fatima N. et al. “Dental Pulp Stem Cells: A New Cellular Resource for Corneal
Stromal Regeneration.” Stem Cells Translational Medicine 4.3 (2015): 276–285. PMC. Web. 22
Apr. 2016.
20: SHANG, K., RNJAK-KOVACINA, J., LIN, Y., HAYDEN, R. S., TAO, H. AND KAPLAN,
D. L. “Accelerated In Vitro Degradation of Optically Clear Low β -Sheet Silk Films by Enzyme-
Mediated Pretreatment” Trans. Vis. Sci. Tech. 2013, 2, 2.
21: “Annealing Metals” http://www.technologystudent.com/equip1/heat3.htm (accessed Apr 24,
2016). Web 23 Apr. 2016
22: SYED-PICARD, F. N., DU, Y., LATHROP, K. L., MANN, M. M., FUNDERBURGH, M.
L. AND FUNDERBURGH, J. L. “Dental Pulp Stem Cells: A New Cellular Resource for Corneal
Stromal Regeneration” Stem Cells Translational Medicine 2015, 4, 276-285.
23: Wang, Hai-Yan, Rui-Hua Wei, and Shao-Zhen Zhao. “Evaluation of Corneal Cell Growth on
Tissue Engineering Materials as Artificial Cornea Scaffolds.”International Journal of
Ophthalmology 6.6 (2013): 873–878. PMC. Web. 25 Apr. 2016.
24: Chirila T, Barnard Z, Zainuddin, Harkin DG, Schwab IR, Hirst L. Bombyx mori silk fibroin
membranes as potential substrata for epithelial constructs used in the management of ocular
surface disorders. 2008;14(7):1203-1211

15. 25: Syed-Picard, Fatima N. et al. “Dental Pulp Stem Cells: A New Cellular Resource for Corneal
Stromal Regeneration.” Stem Cells Translational Medicine 4.3 (2015): 276–285. PMC. Web. 25
Apr. 2016.